94 related articles for article (PubMed ID: 23895888)
21. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma.
Adelstein DJ; Rice TW; Becker M; Larto MA; Kirby TJ; Koka A; Tefft M; Zuccaro G
Cancer; 1997 Sep; 80(6):1011-20. PubMed ID: 9305700
[TBL] [Abstract][Full Text] [Related]
22. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma.
Hong D; Lunagomez S; Kim EE; Lee JH; Bresalier RS; Swisher SG; Wu TT; Morris J; Liao Z; Komaki R; Ajani JA
Cancer; 2005 Oct; 104(8):1620-6. PubMed ID: 16118804
[TBL] [Abstract][Full Text] [Related]
23. Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma.
Elliott JA; O'Farrell NJ; King S; Halpenny D; Malik V; Muldoon C; Johnston C; Reynolds JV
Br J Surg; 2014 Dec; 101(13):1702-11. PubMed ID: 25351460
[TBL] [Abstract][Full Text] [Related]
24. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation.
Javeri H; Xiao L; Rohren E; Komaki R; Hofstetter W; Lee JH; Maru D; Bhutani MS; Swisher SG; Wang X; Ajani JA
Cancer; 2009 Feb; 115(3):624-30. PubMed ID: 19130466
[TBL] [Abstract][Full Text] [Related]
25. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
[TBL] [Abstract][Full Text] [Related]
26. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
Myslivecek M; Neoral C; Vrba R; Vomackova K; Cincibuch J; Formanek R; Koranda P; Zapletalova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
[TBL] [Abstract][Full Text] [Related]
27. Outcomes associated with surgery for T4 esophageal cancer.
Pimiento JM; Weber J; Hoffe SE; Shridhar R; Almhanna K; Vignesh S; Karl RC; Meredith KL
Ann Surg Oncol; 2013 Aug; 20(8):2706-12. PubMed ID: 23504118
[TBL] [Abstract][Full Text] [Related]
28. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status.
Kim MP; Correa AM; Lee J; Rice DC; Roth JA; Mehran RJ; Walsh GL; Ajani JA; Maru DM; Chang JY; Marom EM; Macapinlac HA; Lee JH; Vaporciyan AA; Rice T; Swisher SG; Hofstetter WL
Ann Thorac Surg; 2010 Sep; 90(3):884-90; discussion 890-1. PubMed ID: 20732513
[TBL] [Abstract][Full Text] [Related]
29. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.
Tong DK; Law S; Kwong DL; Chan KW; Lam AK; Wong KH
Ann Surg Oncol; 2010 Aug; 17(8):2184-92. PubMed ID: 20217248
[TBL] [Abstract][Full Text] [Related]
30. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.
Rizk NP; Venkatraman E; Bains MS; Park B; Flores R; Tang L; Ilson DH; Minsky BD; Rusch VW;
J Clin Oncol; 2007 Feb; 25(5):507-12. PubMed ID: 17290058
[TBL] [Abstract][Full Text] [Related]
31. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
[TBL] [Abstract][Full Text] [Related]
32. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
33. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging.
Erasmus JJ; Munden RF; Truong MT; Ho JJ; Hofstetter WL; Macapinlac HA; Correa AM; Wu TT; Bruzzi JF; Marom EM; Sabloff BS; Ajani JA; Komaki R; Liao Z; Lee JH; Fukami N; Bresalier R; Swisher SG
J Thorac Oncol; 2006 Jun; 1(5):478-86. PubMed ID: 17409902
[TBL] [Abstract][Full Text] [Related]
34. Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer.
Hammoud ZT; Kesler KA; Ferguson MK; Battafarrano RJ; Bhogaraju A; Hanna N; Govindan R; Mauer AA; Yu M; Einhorn LH
Dis Esophagus; 2006; 19(2):69-72. PubMed ID: 16643172
[TBL] [Abstract][Full Text] [Related]
35. Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard.
Donohoe CL; O'Farrell NJ; Grant T; King S; Clarke L; Muldoon C; Reynolds JV
Ann Surg; 2013 Nov; 258(5):784-92; discussion 792. PubMed ID: 24045450
[TBL] [Abstract][Full Text] [Related]
36. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R
Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529
[TBL] [Abstract][Full Text] [Related]
37. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma.
Port JL; Lee PC; Korst RJ; Liss Y; Meherally D; Christos P; Mazumdar M; Altorki NK
Ann Thorac Surg; 2007 Aug; 84(2):393-400; discussion 400. PubMed ID: 17643605
[TBL] [Abstract][Full Text] [Related]
38. Accuracy of pathologic examination in detection of complete response after chemoradiation for esophageal cancer.
Chang EY; Smith CA; Corless CL; Thomas CR; Hunter JG; Jobe BA
Am J Surg; 2007 May; 193(5):614-7; discussion 617. PubMed ID: 17434367
[TBL] [Abstract][Full Text] [Related]
39. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results.
Mamede M; Abreu-E-Lima P; Oliva MR; Nosé V; Mamon H; Gerbaudo VH
Am J Clin Oncol; 2007 Aug; 30(4):377-88. PubMed ID: 17762438
[TBL] [Abstract][Full Text] [Related]
40. Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer?
McLoughlin JM; Melis M; Siegel EM; Dean EM; Weber JM; Chern J; Elliott M; Kelley ST; Karl RC
J Am Coll Surg; 2008 May; 206(5):879-86; discussion 886-7. PubMed ID: 18471715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
